数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

股本结构

单位:万股
公告日期 2024-03-27 2024-03-27 2023-11-14 2023-11-14 2023-08-14 2023-08-14
证券总股本 647.68 618.63 617.43 536.03 534.83 529.08
普通股本 647.68 618.63 617.43 536.03 534.83 529.08
优先股 未披露 未披露 未披露 未披露 未披露 未披露
其他 未披露 未披露 未披露 未披露 未披露 未披露
变动日期 2024-03-01 2023-12-31 2023-11-01 2023-09-30 2023-08-01 2023-06-30
注释:中概股证券总股本=普通股股本/ 存托凭证比例

历史变动

公告日期 变动后普通股本(万股) 变动后优先股(万股) 变动原因 变动日期
2024-03-27 647.68 未披露 定期报告 2024-03-01
2024-03-27 618.63 未披露
更多>>
From December 31,2022 to December 31,2023 Issuance of common stock, pre-funded warrants and warrants, net of issuance costs
2023-12-31
2023-11-14 617.43 未披露 定期报告 2023-11-01
2023-11-14 536.03 未披露
更多>>
From June 30, 2023 to September 30, 2023 Issuance of common stock, pre-funded warrants and warrants, net of issuance costs
2023-09-30
2023-08-14 534.83 未披露 定期报告 2023-08-01
2023-08-14 529.08 未披露
更多>>
Inhibikase Therapeutics, Inc. announced that it will effect a 1-for-6 reverse stock split of its common stock.
2023-06-30
2023-06-29 3160.00 未披露 定期报告 2023-06-29
2023-05-15 3105.62 未披露
更多>>
From December 31, 2022 to March 31, 2023 Issuance of common stock, pre-funded warrants and warrants, net of issuance costs
2023-03-31
2023-03-31 2897.72 未披露 定期报告 2023-03-14
2023-01-27 2802.78 未披露
更多>>
Common Stock offered by the company 2,800,789 shares of common stock.
2023-01-27
2022-05-16 2522.71 未披露
更多>>
From December 31, 2021 to March 31, 2022 Issuance of common stock for services Issuance of common stock, stock options exercised
2022-03-31
2022-03-31 2522.71 未披露 定期报告 2022-03-14
2022-02-07 2517.71 未披露 定期报告 2022-02-04
2021-11-15 2515.52 未披露
更多>>
From June 30, 2021 to September 30, 2021 Issuance of common stock, stock options exercised
2021-09-30
2021-08-16 2513.33 未披露
更多>>
From March 31, 2021 to June 30, 2021 Issuance of common stock, follow on offering Issuance of common stock, stock options exercised
2021-06-30
2021-06-18 2513.33 未披露
更多>>
1.Common stock offered 15,000,000 shares 2.The number of shares of common stock to be outstanding after this offering is based on the 10,133,345 shares of common stock outstanding as of June 15, 2021.
2021-06-18
2021-06-11 1013.33 未披露 定期报告 2021-06-07
2021-05-17 1005.98 未披露
更多>>
From December 31, 2020 to March 31, 2021 Issuance of common stock
2021-03-31
2021-03-31 1005.08 未披露
更多>>
From December 31, 2019 to December 31, 2020 Issuance of common stock Conversion of notes Issuance of initial public offering common stock
2020-12-31
2020-12-28 1005.08 未披露
更多>>
1.Common stock offered by the company 1,800,000 shares 2.The number of shares of common stock to be outstanding after this offering is based on the 8,206,706 shares of common stock outstanding as of November 30, 2020
2020-12-23
From December 31,2022 to December 31,2023 Issuance of common stock, pre-funded warrants and warrants, net of issuance costs
From June 30, 2023 to September 30, 2023 Issuance of common stock, pre-funded warrants and warrants, net of issuance costs
Inhibikase Therapeutics, Inc. announced that it will effect a 1-for-6 reverse stock split of its common stock.
From December 31, 2022 to March 31, 2023 Issuance of common stock, pre-funded warrants and warrants, net of issuance costs
Common Stock offered by the company 2,800,789 shares of common stock.
From December 31, 2021 to March 31, 2022 Issuance of common stock for services Issuance of common stock, stock options exercised
From June 30, 2021 to September 30, 2021 Issuance of common stock, stock options exercised
From March 31, 2021 to June 30, 2021 Issuance of common stock, follow on offering Issuance of common stock, stock options exercised
1.Common stock offered 15,000,000 shares 2.The number of shares of common stock to be outstanding after this offering is based on the 10,133,345 shares of common stock outstanding as of June 15, 2021.
From December 31, 2020 to March 31, 2021 Issuance of common stock
From December 31, 2019 to December 31, 2020 Issuance of common stock Conversion of notes Issuance of initial public offering common stock
1.Common stock offered by the company 1,800,000 shares 2.The number of shares of common stock to be outstanding after this offering is based on the 8,206,706 shares of common stock outstanding as of November 30, 2020